Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Naples
Clinical trial register · Italy

Clinical Trials in Naples, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 138 Naples 80 Roma 72 Florence 57 Padova 56
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca80 Hoffmann-La Roche48 Merck Sharp & Dohme LLC40 Bristol-Myers Squibb37 National Cancer Institute, Naples36 Clear sponsor filter
Site location
Milan138 Naples80 Roma72 Florence57 Padova56
All 111 locations
Target enrolment
to

Trials with a site in Naples

80 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
AstraZeneca
Phase 3
2,800
Bari, Bologna, Cosenza, Cremona, Genoa, Milan, Modena, Naples
2026-09-01
Recruiting
AstraZeneca
Phase 3
1,200
Bari, Bologna, Chieti, Milan, Modena, Naples, Roma
2026-07-06
Recruiting
AstraZeneca
Phase 3
150
Aviano, Bergamo, Genova, Milan, Naples
2026-06-15
Recruiting
AstraZeneca
Observational
200
Ancona, Bergamo, Foggia, Meldola, Milan, Modena, Naples, Padova
2026-04-16
Recruiting
AstraZeneca
Phase 3
508
Bologna, Milan, Naples, Rozzano, Torino
2026-02-23
Recruiting
AstraZeneca
Phase 3
1,100
Brescia, Catania, Florence, Lecco, Milan, Naples, Parma, Pisa
2025-12-29
Recruiting
AstraZeneca
Phase 2
230
Modena, Naples, Palermo, Pisa, Roma, Varese
2025-12-10
Recruiting
AstraZeneca
Phase 3
100
Aviano, Florence, Meldola, Milan, Naples, Roma
2025-10-30
Recruiting
AstraZeneca
Phase 1/2
283
Milan, Naples, Roma, Rozzano
2025-10-01
Recruiting
AstraZeneca
Phase 3
700
Arezzo, Bari, Bergamo, Chieti, Genoa, Milan, Naples, Palermo
2025-08-06
Recruiting
AstraZeneca
Phase 2
987
Busto Arsizio, Cuneo, Ferrara, Milan, Monza, Naples, Pavia, Roma
2025-06-27
Recruiting
AstraZeneca
Phase 3
830
Candiolo, Lecco, Lucca, Meldola, Milan, Naples, Peschiera del Garda, Pisa
2025-04-10
Recruiting
AstraZeneca
Phase 3
600
Catania, Florence, Milan, Monza, Naples, Reggio Emilia, Roma, Rome
2025-03-27
Recruiting
AstraZeneca
Phase 3
990
Cona, Florence, Milan, Montebelluna, Naples, Pavia, Roma, Sassari
2025-03-18
Recruiting
AstraZeneca
Phase 2
80
Bologna, Castelfranco Veneto, Florence, Milan, Naples, Pavia, Pisa, Roma
2025-03-12
Recruiting
AstraZeneca
Phase 3
5,000
Bassano del Grappa, Bologna, Desio, Foggia, Genoa, Modena, Naples, Novara
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Cagliari, Florence, Milan, Naples, Padova, Rozzano, Torino, Tricase
2025-03-01
Recruiting
AstraZeneca
Phase 3
744
Bari, Milan, Misterbianco, Monza, Naples, Orbassano, Padova, Parma
2024-10-04
Active, closed
AstraZeneca
Phase 2
194
Genoa, Meldola, Milan, Naples, Orbassano, Perugia, Rozzano, Udine
2024-08-27
Recruiting
AstraZeneca
Phase 3
620
Florence, Milan, Naples, Padova, Roma, Rozzano, Tricase
2024-08-12
Recruiting
AstraZeneca
Phase 3
788
Bergamo, Bologna, Milan, Modena, Naples, Padova, Reggio Emilia, Rome
2024-08-01
Active, closed
AstraZeneca
Phase 3
339
Brescia, Cona, Florence, Milan, Naples, Reggio Emilia, Roma, Rome
2024-06-29
Active, closed
AstraZeneca
Phase 3
2,554
Bologna, Catanzaro, Chiavari, Desio, Milan, Naples, Parma, Rozzano
2024-03-29
Active, closed
AstraZeneca
Phase 3
594
Florence, Milan, Naples, Padova, Pisa, Vicenza
2024-03-04
Active, closed
AstraZeneca
Phase 2
142
Bari, Bologna, Milan, Naples, Palermo, Pavia, Peschiera del Garda
2024-02-22
Recruiting
AstraZeneca
Phase 3
5,250
Ancona, Florence, Genoa, Mestre, Milan, Naples, Pavia, Perugia
2024-02-21
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Bergamo, Bologna, Monza, Naples, Roma
2023-12-29
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Naples, Rome, Brescia, Milan, Rozzano, Turin, Monserrato, Pisa
2023-12-20
Recruiting
AstraZeneca
Phase 3
1,145
Aviano, Florence, Milan, Modena, Naples, Padova, Pavia, Rozzano
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Bergamo, Empoli, Milan, Modena, Naples, Padova, Reggio Emilia, Roma
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Bari, Genoa, Meldola, Milan, Naples, Padova, Rome, Rozzano
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,902
Empoli, Lucca, Milan, Modena, Naples, Padova, Province of Macerata, Roma
2023-11-14
Active, closed
AstraZeneca
Phase 3
1,835
Bergamo, Bologna, Foggia, Genoa, Naples, Pisa, Roma, Torino
2023-11-07
Recruiting
AstraZeneca
Phase 3
800
Bari, Bologna, Catania, Florence, Lecco, Milan, Monza, Naples
2023-09-22
Active, closed
AstraZeneca
Phase 3
111
Milan, Naples, Padova, Pisa, Rozzano, Turin
2023-06-27
Active, closed
AstraZeneca
Phase 2
294
Florence, Milan, Naples, Rozzano
2023-04-24
Active, closed
AstraZeneca
Phase 2
188
Avellino, Brescia, Lecce, Milan, Naples, Palermo, Peschiera del Garda, Reggio Emilia
2023-03-06
Active, closed
AstraZeneca
Observational
551
Naples, Cona, Udine, Rome, Brescia, Milan, Turin, Cagliari
2023-02-27
Active, closed
AstraZeneca
Phase 3
1,350
Florence, Lecco, Messina, Naples, Orbassano, Padova, Parma, Peschiera del Garda
2022-12-29
Recruiting
AstraZeneca
Phase 3
3,527
Arezzo, Brescia, Naples, Roma, Rozzano, Torino
2022-12-13
Active, closed
AstraZeneca
Phase 3
368
Bologna, Milan, Naples, Padova, Pisa, Roma, Rozzano, Verona
2022-11-10
Active, closed
AstraZeneca
Phase 3
594
Aviano, Livorno, Meldola, Milan, Monza, Naples, Padova, Parma
2022-09-15
Recruiting
AstraZeneca
Phase 2
454
Florence, Genova, Milan, Naples, Rome
2022-09-06
Active, closed
AstraZeneca
Phase 2
194
Candiolo, Milan, Naples, Padova, Perugia, Roma, Siena
2022-08-11
Active, closed
AstraZeneca
Phase 3
341
Avellino, Aviano, Catania, Meldola, Milan, Modena, Monserrato, Naples
2022-08-03
Active, closed
AstraZeneca
Phase 3
53
Messina, Naples, Roma
2022-07-01
Active, closed
AstraZeneca
Phase 3
644
Borgo San Lorenzo, Catanzaro, Genova, Livorno, Milan, Modena, Naples, Province of Macerata
2022-05-16
Active, closed
AstraZeneca
Phase 3
390
Bari, Catania, Florence, Genova, Milan, Naples, Padova, Parma
2022-02-21
Active, closed
AstraZeneca
Phase 3
145
Milan, Naples, Roma
2021-11-19
Active, closed
AstraZeneca
Phase 3
148
Arezzo, Avellino, Bari, Bologna, Florence, Meldola, Milan, Naples
2021-10-28
Active, closed
AstraZeneca
Phase 3
927
Bologna, Candiolo, Livorno, Milan, Naples, Negrar, Padova, Roma
2021-10-25
Active, closed
AstraZeneca
Phase 3
732
Bologna, Candiolo, Florence, Meldola, Milan, Naples, Padova, Prato
2021-10-18
Active, closed
AstraZeneca
Phase 3
98
Florence, Meldola, Messina, Naples, Padova, Roma, Terni, Verona
2021-09-12
Active, closed
AstraZeneca
Phase 3
315
Bergamo, Bologna, Florence, Meldola, Milan, Misterbianco, Naples, Padova
2021-06-30
Active, closed
AstraZeneca
Phase 3
506
Ancona, Bergamo, Catania, Milan, Naples, Padova, Prato
2021-06-22
Active, closed
AstraZeneca
Phase 3
893
Bologna, Florence, Misterbianco, Naples, Padova, Prato, Roma
2021-05-10
Active, closed
AstraZeneca
Phase 3
1,157
Bergamo, Candiolo, Genova, Livorno, Milan, Naples, Padova, Rozzano
2021-04-26
Recruiting
AstraZeneca
Phase 1
304
Milan, Monza, Naples, Padova
2021-03-09
Active, closed
AstraZeneca
Phase 3
1,371
Bergamo, Florence, Milan, Modena, Naples, Novara, Padova, Parma
2021-01-28
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Milan, Naples
2020-12-30
Active, closed
AstraZeneca
Phase 1/2
245
Bologna, Milan, Naples, Rome
2020-12-28
Active, closed
AstraZeneca
Phase 1/2
702
Milan, Modena, Naples, Padova, Roma
2020-11-12
Active, closed
AstraZeneca
Phase 3
370
Brescia, Candiolo, Florence, Milan, Modena, Naples, Padova
2020-10-02
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
Milan, Naples, Rome
2020-08-18
Active, closed
AstraZeneca
Phase 2
452
Milan, Naples, Padova, Roma, Verona
2020-06-03
Active, closed
AstraZeneca
Phase 2
240
Bologna, Catanzaro, Meldola, Messina, Milan, Monza, Naples, Roma
2020-04-22
Active, closed
AstraZeneca
Phase 3
818
Bergamo, Candiolo, Catanzaro, Livorno, Meldola, Milan, Modena, Naples
2020-04-16
Active, closed
AstraZeneca
Phase 3
140
Cuneo, Florence, Milan, Naples, Roma, Torino
2019-10-29
Active, closed
AstraZeneca
Phase 2
247
Catania, Naples, Orbassano, Padova, Varese
2019-06-25
Active, closed
AstraZeneca
Phase 3
908
Bologna, Milan, Naples, Roma, Tricase, Lecce, Verona
2019-04-29
Active, closed
AstraZeneca
Phase 3
810
Faenza, Florence, Milan, Naples, Roma, Verona
2019-04-16
Active, closed
AstraZeneca
Phase 3
1,407
Brescia, Lecce, Lecco, Milan, Mirano, Naples, Reggio Calabria, Reggio Emilia
2019-01-04
Active, closed
AstraZeneca
Phase 3
1,063
Bari, Bologna, Florence, Milan, Naples, Orbassano, Pozzuoli, Verona
2018-11-16
Active, closed
AstraZeneca
Phase 3
895
Milan, Naples, Orbassano, Pavia
2018-10-31
Active, closed
AstraZeneca
Phase 3
1,246
Arezzo, Milan, Naples, Orbassano, Parma, Pavia, Roma, Terni
2018-09-27
Active, closed
AstraZeneca
Phase 3
1,324
Benevento, Meldola, Milan, Naples, Perugia, Pisa, Roma, Rozzano
2017-10-11
Active, closed
AstraZeneca
Phase 3
1,126
Arezzo, Meldola, Milan, Naples, Orbassano, Pavia, Roma, San Giovanni Rotondo
2015-11-02
Active, closed
AstraZeneca
Phase 3
510
Bari, Genova, Livorno, Milan, Naples, Orbassano, Parma, Perugia
2013-09-25
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Milan, Modena, Naples, Padova, Roma
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Bari, Catania, Milan, Naples, Padova, Roma
2013-08-26
Rows per page Showing 1–80 of 80
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-italy/city/naples

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 80 of those studies with a site in Naples that also match the filters currently applied.

How many clinical trials are recruiting in Naples?

29 of the 80 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 51 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Naples), 80 studies
PhaseStudiesRecruitingShare
Phase 3582072.5%
Phase 214417.5%
Phase 1/2425%
Observational323.8%
Phase 1111.3%

Most active sponsors

Lead sponsors with the most studies (Naples)
Lead sponsorStudiesRecruiting
AstraZeneca8029
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.